Featured Articles

31. Key Regulatory Considerations For The Next Wave Of Gene Therapies 2/21/2025

    The evolving field of viral vector production, driven by advances in gene and cell therapies, is facing increasing regulatory scrutiny and analytical demands.

32. What The ICH Q5A Virus Safety Guidelines Mean For Your Cell & Gene Therapy Product 2/19/2025

    Explore Cell & Gene therapy (CGT) products now within scope of the ICH Q5A guidance, technologies that can replace traditional testing strategies, viral clearance studies expected for vector products, and more.

33. Limiting Off-Target Effects Of CRISPR-Based Products 2/11/2025

    Find out how to enhance CRISPR gene editing specificity by using Next Generation Sequencing to improve sgRNA quality control, addressing off-target effects and ensuring higher sequence fidelity.

34. Applying Next Generation Sequencing To Accelerate CGT Product Development 2/11/2025

    Next Generation Sequencing (NGS) revolutionizes gene therapy by enhancing the development and safety of viral vectors like AAV and lentivirus. Discover more about its impact.

35. Adapting A Hybrid Analysis For AAV Characterization 2/11/2025

    Gain insights into utilizing hybrid long-read and short-read sequencing to analyze adeno-associated virus capsids to enhance biosafety testing and genome assembly while achieving high identity mapping.

36. Building Local Biomanufacturing Capacity In South Africa 2/11/2025

    Biovac evolved from a vaccine supplier to a biopharmaceutical innovator, providing a blueprint for expanding Africa's vaccine manufacturing capacity. Gain valuable insights from their journey.

37. Bridging Clinical And Commercial Needs 1/29/2025

    Discover how viral vector CDMO services can provide a solution to streamline gene therapy development, balancing clinical and commercial needs, to reduce delays and costs.

38. Optimizing Poloxamer 188 1/13/2025

    Poloxamer 188 stabilizes proteins in liquid formulations and protects cells from shear stress. Molecular weight and hydrophobicity variations influence its effectiveness in different biopharmaceutical applications.

39. Join The Digital Revolution In Supply Chain 12/23/2024

    Explore how the eMERGE™ program digitizes the biopharma supply chain, streamlining raw material receipt, and enhancing efficiency with advanced shipping notifications and integrated systems.

40. If You Can't Win The Game, Change It 12/11/2024

    Explore how eData sharing is used in the biopharma market, enabling standardized, collaborative supply chains that reduce risks and enhance visibility while improving capacity planning.